Ivacaftor (Kalydeco) treatment improves airway flexibility and capacity in patients with cystic fibrosis (CF), according to the results of a study,…
Articles by Patricia Inácio, PhD
Arch Biopartners is collaborating with the University of Cincinnati (UC) for a new drug candidate, AB569, for treating Pseudomonas…
Young children with cystic fibrosis (CF) exhibit a more pro-inflammatory gastrointestinal microbiome, which may underlie impaired nutrient absorption, according to…
A recent study describes a new assay, CFseq, that uses dried blood spots to screen for defects in the gene underlying…
Hepatopulmonary syndrome (HPS), a liver-induced lung disorder, may be underdiagnosed in at-risk patients with cystic fibrosis (CF), according to a study…
Researchers identified a novel, rare mutation causing cystic fibrosis (CF) in a pediatric African-American patient. The mutation, however, was found…
Celtaxsys, a pharmaceutical company focused on novel therapeutics to treat inflammatory diseases, announced that it is beginning enrollment of patients…
In a recent study entitled “Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients,” researchers performed…
Concert Pharma recently announced successful results from a Phase 1 single ascending dose clinical trial for their lead investigational drug CTP-656 as…
In a new study entitled “Cysteamine as a future intervention in cystic fibrosis against current and emerging…